|
|
| Product | Quantum (Rs. Cr) | Long Term Rating | Short Term Rating |
| Bank Loan Ratings | 12.00 | ACUITE B+ | Downgraded | Issuer not co-operating* | - |
| Total Outstanding Quantum (Rs. Cr) | 12.00 | - | - |
| Total Withdrawn Quantum (Rs. Cr) | 0.00 | - | - |
| Rating Rationale |
|
Acuité has downgraded the long term rating to ‘ACUITE B+’ (read as ACUITE B plus) from ‘ACUITE BB-’ (read as ACUITE double B minus) on the Rs. 12.00 crore bank facilities of Impulse Pharma Private Limited(IPPL). The rating continues to be flagged as “Issuer Not-Cooperating” and is downgraded on account of information risk.
|
| About the Company |
|
The Maharashtra-based IPPL was incorporated in 2002 by Dr. D. J Zawar. The company is engaged in manufacturing and market pharmaceutical formulations in the form of tablets and capsules since 2007.
|
| Non-cooperation by the issuer/borrower: |
|
Acuité has been requesting for data, information and undertakings from the rated entity for conducting surveillance & review of the rating. However, the issuer/borrower failed to submit such information before the due date.
Acuité believes that information risk is a critical component in such ratings, and noncooperation by the issuer along with unwillingness to provide information could be a sign of potential deterioration in its overall credit quality. This rating continues to be flagged as “Issuer not-cooperating”, in line with prevailing SEBI regulations and Acuité’s policies. |
| Limitation regarding information availability: |
|
The rating is based on information available from sources other than the issuer/borrower (in the absence of information provided by the issuer/borrower). Acuité endeavored to gather information about the entity/industry from the public domain. Therefore, Acuité cautions lenders and investors regarding the use of such information, on which the indicative credit rating is based.
|
| About the Rated Entity - Key Financials |
|
The rated entity has not shared the latest financial statements despite repeated requests.
|
| Rating Sensitivity |
|
"No information provided by the issuer / available for Acuite to comment upon."
|
| Material Covenants |
|
None
|
| Liquidity Position |
|
"No information provided by the issuer / available for Acuite to comment upon."
|
| Outlook |
|
Not Applicable
|
| Other Factors affecting Rating |
|
None
|
| Status of non-cooperation with previous CRA |
| None |
| Any other information |
|
Acuité is yet to receive the latest No Default Statement (NDS) from the rated entity, despite repeated requests and follow-ups.
|
| Applicable Criteria |
|
• Manufacturing Entities: https://www.acuite.in/view-rating-criteria-59.htm • Default Recognition: https://www.acuite.in/view-rating-criteria-52.htm • Application Of Financial Ratios And Adjustments: https://www.acuite.in/view-rating-criteria-53.htm |
| Note on Complexity Levels of the Rated Instrument |
| https://www.acuite.in/view-rating-criteria-55.htm |
|
| |
|
|
||||||||||||||||||||||||||||||||
|
|
Contacts |
| Analytical | Rating Desk |
| About Acuité Ratings & Research |
| Acuité Ratings & Research Limited | www.acuite.in |
